Newamsterdam Pharma N V (NAMS) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Newamsterdam Pharma Company N v   (NASDAQ: NAMS)

Select the Financial Report: Select the Period:


Description of Newamsterdam Pharma N V's Business Segments
The company operates a single segment focused on the discovery, development, and commercialization of therapies for cardio-metabolic diseases.

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

(Mar 31 2026) three months ended Q1
Business Segments Revenues
(in millions $)		 Income
(in millions $)		 %
(Profit Margin)
Total 3.04 -48.44 -

(Mar 31 2026) three months ended Q1
Revenue Growth rates by Segment Y/Y Revenue
%		 Q/Q Revenue
%
Total 2.08 % 9400 %

(Mar 31 2026) three months ended Q1
Income Growth rates by Segment Y/Y Income
%		 Q/Q Income
%
Total - -


Annual Report on Newamsterdam Pharma Company N v Divisions, Sales by Country

 


Twelve months ended 2025
NAMS s Annual Revenue by Geography and Business Segments Sales
(in millions $)		 %
(of total Sales)
Total 22.50 100 %


Twelve months ended 2025
NAMS s Annual Income by Country and Business Segments Income
(in millions $)		 %
(Profit Margin)
Total -203.82 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Total -50.61 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.